Previous Events

TAVI Today – What’s new in MENA region?
Key Highlights
In addition to treating urgent cases during the pandemic, experts recommend prioritizing AVR for aortic stenosis patients with moderate, but stable symptoms (heart failure symptoms and some degree of LV dysfunction) if hospital resources allow.
A minimalist TAVR approach in appropriately selected patients with short hospitalization may be a better pathway than surgical aortic valve replacement for patients and hospital systems with limited resources and higher risks of Covid-19 infections.
The key factors in evaluating a good TAVR valve are ease of implant, speed of implant, low pacemaker rate, future coronary access, and better outcomes. Experts say it is also important to think about avoiding coronary occlusion because younger patients may need to have the procedure repeated in the future.
The PARTNER 3 Trial demonstrated that the SAPIEN 3 TAVR is superior to surgery in patients with severe symptomatic aortic stenosis at low risk of death from surgery. The data showed better outcomes in multiple areas, including a low death and disabling stroke rate.
Data from clinical trials show that TAVI with newer generation Edwards transcatheter heart valves systems (SAPIEN 3 Ultra) have shown significant improvement in the reduction of paravalvular leak and have been associated with good outcomes.

MENA Webinar: Recent Trends and Treatment
Options Shaping Aortic Valve Therapies
Key Highlights
Over the past 15 years there has been a huge decline in the use of mechanical valves for AVR, with a growing number of younger patients choosing biologic prosthetic valves—despite the significant risk of calcification, degeneration, pannus formation, and thrombosis.
As part of the push to create a longer lasting biologic prosthesis, Edwards developed the INSPIRIS RESILIA valve—which is designed for durability with innovative dry storage technology and new anti-calcification properties.
Pre-clinical data and two ongoing studies (The European Feasibility Study and the COMMENCE Trial) have demonstrated a favorable safety profile and effectiveness for RESILIA tissue through four years of follow up. Tens of thousands of patients worldwide have been implanted with INSPIRIS RESILIA.

COVID-19: Present and Future Considerations
for the Cardiac Surgical Community
Key Highlights
Following the COVID-19 outbreak, many healthcare systems worldwide are gearing towards restoration and recovery of elective surgery.
As part of waiting list management for cardiac surgery, it’s important to stratify patients to determine the priority of surgery and also consider the feasibility of carrying out the procedure.
Many patients across the globe are still fearful of becoming infected with COVID-19 at the hospital and are delaying cardiac surgery.

COVID-19: What Is Important For The Cardiac
Surgical Community
Key Highlights
Patients with CVD who are infected by the virus
have an elevated risk of adverse outcomes.
A recent study from China showed cardiac injury occurred in
20% of COVID-19 patients during hospitalization—and it
was associated with a higher risk of in-hospital mortality.
A panel of international experts has issued several
recommendations to help support critically ill COVID-19 patients
in the ICU as part of the Surviving Sepsis Campaign COVID-19.